EXPLORING THE POTENTIAL OF Morindia citrifolia IN TUBERCULOSIS: A NETWORK PHARMACOLOGICAL APPROACH

Abstract

Global mortality rates from tuberculosis (TB) are high, and the disease is still progressive and thriving. Myobacterium tuberculosis (Mtb) has developed a resistance to anti- tuberculosis drugs such as rifampin and moxifloxacin. It poses a serious obstacle to it treatment, increasing allelopathic medicines more difficult to administer and resulting in life- threatening health issues. Alternative therapeutic approaches are imperative, especially via investigating phytochemicals from medicinal plant like Morindia citrifolia as possible TB inhibitor. Phytochemicals (Nordamnacanthal, Ricinoleic acid, Kaempferol, Octanoic acid, 3-methylbut-2-enyl ester) originating from different parts of plant are recognized for their various advantageous characteristics , such as antibactertial, anti- inflammatory , anti- tuberculosis, and disease- modifying abilities. Because these phytochemicals reduce the virulence of disease and eradicate multi- drug resistance, they have demonstrated promise in the treatment of chronic disease, including TB. An effective method for determining these phytochemicals' capacity to suppress Mycobacterium TB at the early stages of infection is through in silico research. When screening plant phytochemicals, computational techniques are important. This study makes use of a range of computer methods such as network pharmacology and molecular docking to predict the phytochemicals from Morindia citrifolia on the molecular processes connected to tuberculosis. The work investigates the main objective for developing precision medicine. The results of the study suggest that Morindia citrifolia may be utilized to treat tuberculosis. Natural supplements are reliable and secure substitute for traditional tuberculosis therapies. This study highlights how crucial it is to look into the potential application of natural compunds as a molecular tuberculosis (TB) treatment.